Checkpoint Therapeutics Reports Full-Year 2020 Financial Results and Recent Corporate Highlights
March 09, 2021 16:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
Checkpoint Therapeutics to Participate in H.C. Wainwright Global Life Sciences Virtual Conference
March 04, 2021 08:00 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James...
Checkpoint Therapeutics Announces Formation of Scientific Advisory Board
March 01, 2021 08:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the formation...
Checkpoint Therapeutics to Participate in Three January 2021 Virtual Investor Conferences
January 06, 2021 08:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James...
Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
November 09, 2020 08:00 ET
|
Checkpoint Therapeutics, Inc
44.0% objective response rate and 10.3-month median progression-free survival observed in non-small cell lung cancer (NSCLC) cohortPhase 3 registration-enabling trial planned in first-line metastatic...
Checkpoint Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights
November 04, 2020 16:25 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition,...
Checkpoint Therapeutics Announces $20.0 Million Bought Deal Offering
September 17, 2020 17:27 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today...
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
September 17, 2020 06:30 ET
|
Checkpoint Therapeutics, Inc
51.4% objective response rate and 13.5% complete response rate in half the planned pivotal cohortInterim results presented at ESMO Virtual Congress 2020On track to report full top-line results in...
Checkpoint Therapeutics to Participate in Three September 2020 Virtual Investor Conferences
September 10, 2020 08:00 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James F....
Checkpoint Therapeutics to Present at Virtual Corporate Access Summit Hosted by B. Riley FBR on Wednesday, August 19, 2020
August 17, 2020 08:00 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James F....